The Dutch insulin pump maker continues to expand its senior leadership as it looks to advance its Kaleido patch pump system. It appointed Karen Baxter, former VP and GM at Dexcom, to the position of SVP of sales for Europe. The company also named Jay Little, a longtime commercialization and market access executive at Medtronic Diabetes — where CEO Tom Arnold previously spent six years — as the company’s newly established VP of strategy and business development.
Baxter and Little bring close to a combined 40 years of experience commercializing diabetes-related medical devices. They join following the company’s $85 million funding round announced last month. Arnold told Drug Delivery Business News that ViCentra plans for a big commercial push with Kaleido after the funding. The new hires should help accelerate the reach of Kaleido across Europe into new markets, the company says.
“These are transformative additions to our leadership team,” said Arnold. “Karen brings an exceptional track record of scaling category-defining diabetes businesses across Europe through both direct sales as well as distributors. Jay adds deep strategic expertise in partnerships, reimbursement, and commercial execution. With their leadership, ViCentra is well-positioned to bring the Kaleido experience to more people living with diabetes.”
(Read also: How ViCentra built the smaller, more precise Kaleido insulin patch pump)
Kaleido, described by the company as the smallest, lightest and most precise insulin patch pump in its class, offers premium materials and customizable aluminum shells in 10 color options to deliver the feel of personal technology rather than a traditional medical device. It integrates with Diabeloop’s self-learning automated insulin delivery algorithm and Dexcom’s leading continuous glucose monitors (CGMs).
The pump offers users options in terms of wearability and comes with two durable, rechargeable pumps, eliminating the need to dispose of the pump every three days, while the infusion set lasts for that three-day span. The design aims to integrate seamlessly into the user’s daily life.
Kaleido initially won CE mark back in October 2024. In August, the company announced its plans to launch its next-generation pump in Germany and the Netherlands in early 2026.
More about Karen Baxter
Baxter brings nearly two decades of commercial experience specifically in European diabetes markets, ViCentra said.
Most recently, she spent nine years at Dexcom, serving as VP and GM for Northern Europe and select international markets. In her time at Dexcom, Baxter launched and scaled the CGM maker’s UK and Ireland business to more than $200 million in annual revenue.
Additionally, Baxter built a commercial team of more than 250 employees and helped deliver more than $1 billion in cumulative regional sales. ViCentra said she brings expertise in market entry, reimbursement and commercial execution across Europe’s healthcare systems.
“I am thrilled to join ViCentra at such a pivotal stage in its growth,” said Baxter. “Kaleido’s user-centered design and lifestyle-first approach truly sets it apart, offering people with diabetes greater freedom, comfort, and discretion in their insulin therapy. I am excited to collaborate with our teams and clinical partners to expand access, drive adoption, and bring this premium, life-enhancing experience to more people across Europe.”
More about Jay Little
Little spent 18 years at Medtronic Diabetes (soon to be MiniMed), garnering experience in strategic growth, market access and partnerships.
At Medtronic, Little led payer strategy, value-based care initiatives and large-scale partnerships. He also brings expertise in reimbursement and access strategy for new product launches, enterprise contracting and cross-functional commercialization.
ViCentra said Little’s responsibilities now include corporate strategy and business development. The company aims for him to support long-term scalability, commercial readiness and strategic partnerships. Focuses include building strategic alliances, optimizing market development pathways and advancing growth ambitions.
“ViCentra distinguishes itself through a compelling fusion of design, precision, and purpose. The momentum behind Kaleido is both strong and growing, underscoring its potential to reshape diabetes care,” said Little. “Throughout my career, I have been committed to expanding access to diabetes technology that truly improves lives. This is the right team and the right time to make a bigger impact. I am excited to build the partnerships and strategies needed to bring Kaleido’s innovative, user-centered insulin delivery to more people.”
